Dario Sterker

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 529 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 132 citations · Full text

Medicine, Cancer Biology, Oncology +15

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp et al. · Cancer Cell · 2015 · 123 citations · Full text

Medicine, Oncology, Pharmacology +8

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis et al. · Molecular Cancer Therapeutics · 2012 · 120 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann et al. · Journal of Medicinal Chemistry · 2020 · 113 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15